EuroVacc’s primary objectives
Promote HIV vaccine research
To promote HIV vaccine research by bridging the strength of academic research groups with industrial expertise
Facilitate and support phase I & II clinical trials in Europe
To facilitate and support phase I & II clinical trials in Europe to expedite translational research from discovery to clinical development;
Partner with other international initiative
To partner with other international initiatives and industry for down-stream development and phase IIb/III trials.
Development of safe and effective HIV vaccines
EuroVacc is a non-profit organization dedicated to the development of safe and effective HIV vaccines through promoting and fostering collaborations with world leading HIV Vaccine researchers and developers in both public and private sectors.
Discovery Program and Clinical trials
The primary focus of EuroVacc’s scientific program is on facilitating translational research from discovery to early phase I/II clinical development. With regard to the discovery program, EuroVacc’s lead vaccine platform is poxvirus-based vaccine, in particular NYVAC. With regard to the clinical development program, EuroVacc has sponsored or co-sponsored multiple phase I/II clinical trials in Europe and Africa, in both prophylactic and therapeutic settings.